YLYanjing Li

Yanjing Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yanjing Li has a total of 98 co-authors. Here are the top co-authors by number of shared publications:

  • Ling Qi

    12 shared publications
  • Lisha Li

    Department of Gastrointestinal Oncology Harbin Medical University Cancer Hospital Harbin Heilongjiang China

    10 shared publications
  • Mingxia Jiang

    Department of Gastrointestinal Oncology Harbin Medical University Cancer Hospital Harbin Heilongjiang China

    10 shared publications
  • Junqing Gan

    Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, 150 Haping St, Nangang District, Harbin, Heilongjiang, 150081, PR China

    8 shared publications
  • Yuxian Bai

    Harbin Medical University Cancer Hospital, Harbin, China

    8 shared publications
  • Dongfeng Song

    Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, 150 Haping St, Nangang District, Harbin, Heilongjiang, 150081, PR China

    6 shared publications

Latest Publications

  • Open Access

    Silk-coated PLGA non-spherical microparticles for simvastatin delivery in rat maxillofacial bone regeneration

    by Junjiang Zhang, Yuqi Chang, Yiwen Zhou, Yang Zhou, Jiayin Li, Feng Wang, Zhimin Zhou, Lei Sui, Yanjing Li

    Maxillofacial bone defects present a major challenge in clinical practice. Bone grafting and bone tissue engineering are limited by various side effects and potential risks, while local drug delivery is regarded as a convenient and efficient strategy for bone repair and regeneration. However, for bone tissue regeneration, a drug delivery system should not only release osteogenic drugs but also possess an appropriate morphology to provide structural support for cell proliferation and differentiation. Polymeric non-spherical counterparts may offer new osteogenic properties through altered cellular interactions, biodistribution, and immune responses, compared with spherical drug carriers. Poly(lactic-co-glycolic acid) (PLGA) has been widely used to prepare various drug carriers due to its excellent biocompatibility and controllable biodegradation. Shape regulation, surface modification and drug incorporation are effective approaches to impart distinct functions to PLGA particles for various biomedical applications. However, PLGA has inherent limitations, including poor hydrophilicity, acidic degradation products and a lack of functional ligands for cell attachment, which hinder its effectiveness in bone regeneration. To solve these problems, natural proteins were utilized to improve the bone/cartilage regeneration of polymeric particles/scaffolds through surface modification or physical complexation due to their excellent biocompatibility and biodegradability. In this study, we successfully developed simvastatin (SIM)-loaded disc-shaped PLGA microparticles with coarse surface (dPLGA) using W1/O/W2 followed by silk fibroin (SF) coating for hydrophilicity and biocompatibility improvement. In vitro and in vivo experiments revealed that SF-modified SIM-loaded dPLGA (SF-SIM@dPLGA) significantly promoted the osteogenic differentiation of stem cells and bone regeneration in cranial bone defects, indicating the superior osteoconductive and osteoinductive advantages arising from the physical morphology of particles and chemical effects. Additionally, SF-SIM@dPLGA demonstrated improved tissue adhesion and hemostatic ability. This novel PLGA non-spherical particle-based local delivery system provides a feasible strategy for practical maxillofacial bone repair due to the simple preparation procedures and enhanced bone regeneration performance.

  • Open Access

    FAM83A may serve as a potential prognostic indicator for stomach adenocarcinoma

    by Dong-Feng Song, Ze-Qing Gu, Ling Qi, Yi-Ming Wu, Li Wang, Meng-Ru Jin, Zhi-Guo Li, Yan-Jing Li

    Background: Currently, gastric cancer clinical biomarkers are susceptible to interference, causing low specificity or sensitivity. Some also fail to reflect molecular heterogeneity and predict prognosis individually, so urgent clinical need exists for new biomarkers. FAM83A is a member of the family with sequence similarity 83 (FAM83) family, which could predict the prognosis of lung adenocarcinoma (LUAD). However, the relationship between FAM83A and stomach adenocarcinoma (STAD) prognosis remains unclear. Therefore, this study aims to investigate the expression of FAM83A in STAD and its role in predicting prognosis, with the aim of providing novel potential prognostic biomarkers for clinical practice. Methods: We obtained The Cancer Genome Atlas (TCGA)/Genotype-Tissue Expression (GTEx) of 408 STAD patients via the Gene Expression Profiling Interactive Analysis (GEPIA), collected 70 post-radical resection gastric cancer patient samples from Harbin Medical University Cancer Hospital, and retrieved patient information from the hospital’s electronic medical record system. Telephone follow-ups were performed bimonthly until overall survival (OS) endpoint or last follow-up date. Tumor recurrence or metastasis was determined through a combination of imaging examinations (e.g., computed tomography), and the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria were used primarily to evaluate treatment response during follow-up. Additionally, Western blot, immunohistochemistry (IHC), SPSS 25.0 and MedCalc 20.1.0 were used to detect the expression of FAM83A and its clinical significance. Results: Seventy post-radical gastrectomy STAD patients were enrolled (56 male, 14 female), including 6 well-, 24 moderately-, and 40 poorly-differentiated cases. According to the pathological tumor node metastasis (pTNM) stage, 3, 15, and 52 patients were in stages I, II, and III, respectively. Western blot of tumor tissues and TCGA/GTEx database analysis revealed FAM83A overexpression in STAD. IHC showed 70% (n=49) of samples had high FAM83A expression, while 30% (n=21) had low expression. Moreover, the expression of FAM83A was associated with pTNM stage (P=0.02) and primary tumor (pT) classification (P=0.001). Kaplan-Meier analysis revealed low FAM83A expression was associated with better OS and disease-free survival (DFS). In addition, Cox univariate analysis revealed high FAM83A expression was associated with poorer OS [hazard ratio (HR) =2.082, 95% confidence interval (CI): 1.153–3.761; P=0.02] and DFS (HR =1.814, 95% CI: 1.005–3.276; P=0.048) in STAD patients. Cox multivariate analysis showed that pTNM stage and lymph node metastasis were independent prognostic factors for OS and DFS, respectively. However, FAM83A lost significance for both OS and DFS in multivariate analysis, possibly due to limited sample size or interactions with other covariates. Conclusions: FAM83A may serve as a potential indicator of STAD prognosis, but its clinical application requires further validation in studies with larger sample sizes and prospective designs. Future studies are needed to validate the prognostic value of FAM83A through signaling pathway mechanism research and independent cohort verification.

  • 5-ALA mediated PDT induces pyroptosis in colorectal cancer cells by targeting the caspase-1/GSDMD pathway

    by Ding-Yuan Zhang, Zeqing Gu, Luyao Shi, Zhongshi Li, Xiaoxue Du, Yanjing Li

    Photodynamic therapy (PDT) is a minimally invasive treatment modality based on photochemical reactions that damage specific tumour tissues. Pyroptosis is a type of programmed death that relies on the activation of cysteine-containing aspartate proteolytic enzymes (caspases) and cleavage of the gasdermin protein family members. However, the mechanism of 5-aminolevulinic acid (5-ALA)-mediated PDT-induced pyroptosis in colorectal cancer is not well understood. Here, we found that 5-ALA-mediated PDT can induce pyroptosis in colorectal cancer cells, characterized by the appearance of pyroptotic bubbles and the detection of the release of cellular contents and inflammatory factors. Mechanistically, PDT activates caspase-1 and cleaves gasdermin D (GSDMD), and the release of N-GSDMD triggers pyroptosis in colorectal cancer cells. In addition, inhibition of this pathway in vivo can attenuate the therapeutic effect of PDT. In summary, we investigated the role of GSDMD in PDT-mediated pyroptosis in CRC cells, and the results showed that 5-ALA-mediated PDT induces pyroptosis in colorectal cancer cells by targeting the caspase-1/GSDMD pathway. This study may provide a reference for the clinical application of PDT in CRC treatment.


  • Open Access

    The impact of JMJD5 on tumorigenesis: a literature review

    by Ling Qi, Jing-Wen Zhou, Yong-Chen Zhang, Xiao-Dong Ling, Ming-Xia Jiang, Li-Sha Li, Yan-Jing Li

    Cancer remains one of the leading causes of global mortality, with dysregulated epigenetic regulators playing pivotal roles in tumorigenesis. Among these, Jumonji C domain-containing protein 5 (JMJD5/KDM8), an assigned protein hydroxylase/histone demethylase, exhibits context-dependent oncogenic or tumor-suppressive functions across malignancies. While JMJD5 is significantly overexpressed in breast, colon, oral squamous cell carcinoma, prostate cancer, and atypical meningiomas, its downregulation is observed in liver and lung cancers, highlighting its paradoxical roles in cancer biology. This review systematically examines JMJD5’s multifaceted mechanisms in tumor progression, including its regulation of apoptosis, modulation of glucose metabolism, promotion of metastatic dissemination, and acceleration of cell cycle progression. We further discuss the therapeutic implications of JMJD5 targeting, emphasizing its potential as a novel epigenetic vulnerability for precision oncology strategies.

  • Retracted
    Open Access

    RETRACTED ARTICLE: Dihydroartemisinin enhances the anti-tumour effect of photodynamic therapy by targeting PKM2-mediated glycolysis in oesophageal cancer cell

    by Mengru Jin, Luyao Shi, Li Wang, Dingyuan Zhang, Yanjing Li

    Photodynamic therapy (PDT) has been demonstrated to provide immediate relief of oesophageal cancer patients' re-obstruction and extend their lifespan. However, tumour regrowth may occur after PDT due to enhanced aerobic glycolysis. Previous research has confirmed the inhibitory effect of Dihydroartemisinin (DHA) on aerobic glycolysis. Therefore, the current study intends to investigate the function and molecular mechanism of DHA targeting tumour cell aerobic glycolysis in synergia PDT. The combined treatment significantly suppressed glycolysis in vitro and in vivo compared to either monotherapy. Exploration of the mechanism through corresponding experiments revealed that pyruvate kinase M2 (PKM2) was downregulated in treated cells, whereas overexpression of PKM2 nullified the inhibitory effects of DHA and PDT. This study proposes a novel therapeutic strategy for oesophageal cancer through DHA-synergized PDT treatment, targeting inhibit PKM2 to reduce tumour cell proliferation and metastasis.


  • Framework Nucleic Acids: A Promising Vehicle for Small Molecular Cargos

    by Junjiang Zhang, Jiayin Li, Lei Sui, Yanjing Li

    Framework nucleic acids (FNAs), which are a series of self-assembled DNA nanostructures, are highly versatile tools for engineering intelligent molecular delivery vehicles. Owing to their precise and controllable design and construction, excellent programmability and functionality, as well as favorable intercalation between DNA and small molecules, FNAs provide a promising approach for small molecule delivery. This review discusses the advantages, applications, and current challenges of FNAs for the delivery of small molecular cargo. First, the physicochemical and biological properties that make FNAs favorable for the transport of small molecules are introduced. Thereafter, the classification of loaded cargos and the mechanism of combination between small molecules and FNAs are summarized in detail, and recent research on FNA-based delivery systems and their applications are highlighted. Finally, the challenges and prospects of FNA nanocarriers are discussed to advance their exploitation and clinical adoption.


  • Caspase‐6 is a key regulator of cross‐talk signal way in PANoptosis in cancer

    by Ling Qi, Li Wang, Mengru Jin, Mingxia Jiang, Lisha Li, Yanjing Li

    Cysteinyl aspartate specific proteinase (caspase)‐6 belongs to the caspase family and plays a vital role in mediating cell death. Under certain conditions, three pathways of programmed cell death (PCD), including apoptosis, necroptosis and pyroptosis (PANoptosis), transform one way into another, with enormous therapeutic potential. Initially, scholars reported that caspase‐6 is a caspase executor that mediates apoptosis. With the ceaseless exploration of the PCD types, studies have demonstrated that caspase‐6 mediates pyroptosis by regulating gasdermin D and mediates necroptosis by regulating mixed lineage kinase domain‐like. By regulating PANoptosis, caspase‐6 plays a crucial role in tumorigenesis in humans and mediates anti‐tumour immunity. Therefore, a comprehensive understanding of caspase‐6 function in cancer via PANoptosis is important for the prevention and therapy of tumours. This article summarized the function of caspase‐6 in PANoptosis and its impact on cancer development, providing targets and strategies for tumour treatment.


  • Corrigendum to “Photodynamic therapy induces human esophageal carcinoma cell pyroptosis by targeting the PKM2/caspase-8/caspase-3/GSDME axis” [Cancer Lett. 520 (2021) 143–159]

    by Lisha Li, Dongfeng Song, Ling Qi, Mingxia Jiang, Yiming Wu, Junqing Gan, Kui Cao, Yanjing Li, Yuxian Bai, Tongsen Zheng